GO:0048406 nerve growth factor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0048406 (nerve growth factor binding) is a molecular function defined as binding to nerve growth factor (NGF), the founding member of the neurotrophin family.
• NGF binding is mediated by two classes of receptors: the high-affinity tropomyosin receptor kinase A (TRKA/NTRK1) and the low-affinity p75 neurotrophin receptor (p75NTR/NGFR).
• The NGF dimer engages TRKA to trigger autophosphorylation and downstream MAPK, PI3K-AKT and PLC-gamma signaling that control neuronal survival, differentiation and nociception.
• NGF binding is not limited to the nervous system; it also modulates immune and inflammatory responses, ocular allergy, alcohol use disorders and cancer progression.
• ATP binding to NGF and proNGF acts as an endogenous molecular switch that can modulate neurotrophin activity and receptor engagement.
• The NGF R100E mutation alters pain behavior, joint inflammation and bone erosion in a sex-dependent manner in mice, showing that NGF binding interfaces are functionally tunable.
Description
GO:0048406, nerve growth factor binding, is a molecular function ontology term describing the selective interaction of a protein with nerve growth factor (NGF). NGF is the prototype neurotrophin, a secreted dimeric polypeptide that controls the survival, differentiation and maintenance of sympathetic and sensory neurons. The term captures the binding event itself, independent of whether the binding protein is a signaling receptor, a co-receptor, a matrix protein or an antibody. Because NGF is a central regulator of neuronal and non-neuronal physiology, proteins annotated with GO:0048406 are of broad interest in neurobiology, pain research, immunology and oncology. At the molecular level, NGF binding is best understood through its canonical receptors. The high-affinity receptor TRKA (encoded by NTRK1) binds NGF dimers and undergoes autophosphorylation, while the low-affinity receptor p75NTR (encoded by NGFR) binds all neurotrophins and modulates signaling and cell fate. Structural and biochemical studies have defined the NGF dimer interface and the receptor-binding surfaces that underlie this specificity. More recent work has shown that ATP binding to NGF and proNGF can act as an endogenous molecular switch, adding a layer of metabolic regulation to neurotrophin activity. For researchers, GO:0048406 is a practical annotation target. It is used to classify gene products in functional enrichment analyses, to interpret CRISPR screens and interactome data, and to design assays that measure NGF-receptor engagement. Because NGF signaling is implicated in diabetic neuropathy, alcohol use disorders, ocular allergy, inflammatory pain and colorectal cancer metastasis, the term connects basic neurotrophin biology to clinically relevant phenotypes.
nerve growth factor binding At A Glance
| GO ID | GO:0048406 |
|---|---|
| GO term | nerve growth factor binding |
| Ontology | molecular_function |
| Definition | Binding to nerve growth factor (NGF). |
| Synonym | beta-nerve growth factor binding; neurotrophin TRKA receptor activity; NGF binding |
| Major function | Selective non-covalent interaction with NGF, enabling receptor activation, transport or sequestration of the neurotrophin. |
| Canonical binding partners | TRKA (NTRK1) high-affinity receptor and p75NTR (NGFR) low-affinity receptor. |
| Ligand | NGF, a dimeric neurotrophin and founding member of the neurotrophin family. |
| Related disease areas | Diabetic neuropathy, alcohol use disorders, ocular allergy, inflammatory pain, colorectal cancer. |
What Is GO:0048406?
In plain terms, GO:0048406 describes the ability of a protein to physically bind nerve growth factor (NGF). The QuickGO definition states that this molecular function is simply binding to NGF. It does not require that the binding protein be a receptor or that any downstream signal be transmitted; it only requires a selective, non-covalent interaction with NGF. Synonyms include beta-nerve growth factor binding, neurotrophin TRKA receptor activity and NGF binding. The term is therefore broader than receptor activity and can be used to annotate receptors, co-receptors, carrier proteins, extracellular matrix components and engineered binders such as antibodies.
Why Is nerve growth factor binding Important in Cell Biology?
Nerve growth factor binding is important because it is the first committed step in NGF signaling, a pathway that governs neuronal survival, nociceptor sensitization, immune modulation and tumor progression. Annotating a protein with GO:0048406 immediately places it in a well-defined functional network that includes TRKA, p75NTR and downstream MAPK, PI3K-AKT and PLC-gamma cascades. This makes the term valuable for interpreting genome-wide screens, for prioritizing drug targets in pain and neuropathy, and for understanding how endogenous molecules such as ATP can tune neurotrophin activity. It also provides a mechanistic bridge between neurobiology and immunology, since NGF binding influences allergic inflammation and alcohol-related pathology.
• Defines the entry point of NGF signaling through TRKA and p75NTR, two receptors with distinct downstream outputs.
• Underpins neuronal survival, differentiation and maintenance of sympathetic and sensory neurons.
• Contributes to pain sensitization and inflammatory joint disease, as shown by the NGF R100E mutation in mice.
• Is implicated in diabetic neuropathy, a major complication of diabetes.
• Is linked to alcohol use disorders through NGF signaling in the central nervous system.
• Plays a role in ocular allergy and neurogenic inflammation at mucosal surfaces.
• Promotes colorectal cancer metastasis by orchestrating NGAL and matrix metalloproteinases.
• Provides a target for anti-NGF monoclonal antibodies such as bedinvetmab in veterinary medicine.
• Can be modulated by ATP binding to NGF and proNGF, revealing a metabolic switch on neurotrophin activity.
• Serves as a functional annotation node in enrichment analyses of neurotrophin-related datasets.
Molecular Mechanism of nerve growth factor binding
NGF dimer recognition and receptor engagement
In simple terms: NGF is a two-part molecule, and the binding protein must recognize the paired surface of the NGF dimer.
NGF is a non-covalent homodimer, and its receptor-binding surfaces are formed by the dimer interface and adjacent loops. The high-affinity receptor TRKA binds the NGF dimer with nanomolar affinity, while p75NTR binds all neurotrophins with lower affinity. Structural studies have defined the cysteine-knot fold of NGF and the residues that contact TRKA, providing a template for understanding how GO:0048406-annotated proteins achieve specificity.
TRKA activation and autophosphorylation
In simple terms: When TRKA binds NGF, it pairs up and switches on its own kinase activity.
NGF binding induces TRKA dimerization and trans-autophosphorylation of tyrosine residues in the intracellular kinase domain. These phosphotyrosines recruit adaptor proteins such as SHC and PLC-gamma, leading to activation of the MAPK, PI3K-AKT and PLC-gamma pathways. This cascade is the principal mechanism by which NGF binding is converted into changes in gene expression, neuronal survival and nociceptor excitability.
p75NTR modulation and co-receptor function
In simple terms: The low-affinity receptor p75NTR can fine-tune or sometimes oppose TRKA signals.
p75NTR (NGFR) binds NGF and other neurotrophins and can modulate TRKA signaling, influence cell survival or death decisions, and interact with co-receptors such as sortilin for proNGF binding. The balance between TRKA and p75NTR engagement is a key determinant of whether NGF binding promotes survival, differentiation or apoptosis in a given cell context.
ATP as an endogenous molecular switch on NGF and proNGF
In simple terms: ATP can stick to NGF and change how it behaves, acting like a built-in dimmer switch.
Recent biochemical work has shown that ATP binds to NGF and proNGF and acts as an endogenous molecular switch that modulates neurotrophin activity. This finding expands the regulatory landscape of GO:0048406 by showing that the ligand itself can be chemically modified by a small metabolite, potentially altering receptor engagement and downstream signaling.
Therapeutic and engineered NGF binders
In simple terms: Antibodies and engineered proteins can also bind NGF and block its action.
Anti-NGF monoclonal antibodies such as bedinvetmab bind NGF and prevent receptor activation, which is the basis for their use in veterinary pain management. These biologics demonstrate that GO:0048406 is not restricted to natural receptors; any protein that selectively binds NGF can be annotated with this function, including therapeutic antibodies and designed binding scaffolds.
Key Genes Involved in GO:0048406 nerve growth factor binding
The following genes encode proteins that bind NGF directly or are core components of the NGF binding and signaling machinery.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NGF | Ligand; dimeric neurotrophin that is bound by GO:0048406-annotated proteins | Central to neurotrophin biology and pain research |
| NTRK1 | High-affinity NGF receptor TRKA; mediates survival and differentiation signals | Key target in neuropathy and cancer |
| NGFR | Low-affinity p75 neurotrophin receptor; modulates TRKA signaling and cell fate | Important in neuronal death and immune regulation |
| SORT1 | Sortilin co-receptor for proNGF; influences proNGF binding and trafficking | Relevant to proNGF biology and neurodegeneration |
| SHC1 | Adaptor recruited to phosphorylated TRKA after NGF binding | Readout of TRKA activation |
| PLCG1 | Phospholipase C gamma 1; downstream effector of TRKA | Links NGF binding to calcium and PKC signaling |
| MAPK1 | ERK2; downstream kinase in NGF-induced MAPK cascade | Common readout in NGF signaling studies |
| AKT1 | PI3K-AKT survival kinase activated by NGF binding | Survival signaling node |
| NGAL | Neutrophil gelatinase-associated lipocalin; induced in NGF-driven cancer models | Linked to colorectal cancer metastasis |
| MMP2 | Matrix metalloproteinase 2; activity orchestrated by NGF in cancer | Invasion and metastasis research |
| MMP9 | Matrix metalloproteinase 9; activity orchestrated by NGF in cancer | Invasion and metastasis research |
| TNF | Inflammatory cytokine influenced by NGF signaling | Relevant to ocular allergy and inflammation |
| IL4 | Cytokine implicated in allergic responses modulated by NGF | Ocular allergy research |
| BDNF | Related neurotrophin that can compete or cooperate at neurotrophin receptors | Comparative neurotrophin studies |
| NTF3 | Neurotrophin 3; related family member for specificity comparisons | Neurotrophin family research |
| NTF4 | Neurotrophin 4; related family member for specificity comparisons | Neurotrophin family research |
| NTRK2 | TRKB receptor; related to TRKA for comparative binding studies | Neurotrophin receptor family research |
How Is nerve growth factor binding Regulated?
NGF binding is regulated at multiple levels. The availability of mature NGF is controlled by proteolytic processing of proNGF, and proNGF itself can bind receptors with different outcomes. ATP binding to NGF and proNGF acts as an endogenous molecular switch that can modulate neurotrophin activity, adding a metabolic layer of control. Receptor levels and trafficking also determine the strength and duration of NGF binding; TRKA and p75NTR can be internalized, degraded or recycled, and their ratio influences whether NGF promotes survival or death. In disease contexts, inflammatory mediators and cytokines can alter NGF expression and receptor sensitivity, as seen in ocular allergy and alcohol use disorders.
nerve growth factor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NGF | Diabetic neuropathy; pain; cancer metastasis | NGF knockout or point-mutation models in mice |
| NTRK1 | Neuropathy; pain; cancer | TRKA knockout or kinase-dead knock-in cells |
| NGFR | Neuronal death; immune modulation | p75NTR knockout mice or cells |
| NGF (R100E) | Inflammatory joint pain and bone erosion | Targeted NGF R100E point-mutation mouse |
| NGAL/MMP9 | Colorectal cancer metastasis | Xenograft models with NGF-overexpressing tumor cells |
NGF binding in diabetic neuropathy
Diabetic neuropathy is a common complication of diabetes in which sensory and autonomic nerve function is impaired. NGF and its binding receptors have been studied as key mediators of neuronal maintenance, and altered NGF signaling is associated with the development of neuropathy. Because GO:0048406 defines the binding step that initiates NGF signaling, proteins annotated with this function are candidate modifiers of neuropathy progression and potential therapeutic targets.
NGF binding in alcohol use disorders
NGF signaling has been implicated in alcohol use disorders, where neurotrophin dysregulation may contribute to neuroadaptation and withdrawal-related pathology. The binding of NGF to its receptors is the first step in this pathway, making GO:0048406-annotated proteins relevant to studies of alcohol-related brain changes and potential pharmacologic interventions.
NGF binding in ocular allergy
Neurotrophic factors, including NGF, participate in ocular allergy and neurogenic inflammation at the ocular surface. NGF binding to receptors on immune and structural cells can amplify allergic responses, and modulating this interaction is an area of clinical interest.
NGF binding in cancer metastasis
NGF signaling can promote tumor progression. In colorectal cancer, NGF orchestrates NGAL and matrix metalloproteinase activity to promote metastasis. NGF binding to receptors on tumor cells or stromal cells is therefore a potential node for anti-metastatic strategies, and GO:0048406 provides a functional annotation for the proteins involved.
From nerve growth factor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of NGF binding abolish TRKA signaling? | NTRK1 knockout cell line |
| Does a specific NGF interface residue control pain behavior? | NGF R100E point-mutation knock-in mouse |
| Can a tagged NGF receptor be used to map binding sites? | Tagged knock-in of NTRK1 or NGFR |
| Does overexpression of NGF drive metastasis? | NGF overexpression in colorectal cancer cells |
| Can an anti-NGF antibody block receptor binding? | In vitro binding assay with bedinvetmab or similar antibody |
| Does ATP modulate NGF-receptor engagement? | Biochemical binding assays with ATP and NGF/proNGF |
How to Study the nerve growth factor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Surface plasmon resonance | Binding affinity and kinetics | NGF-TRKA interaction studies |
| Isothermal titration calorimetry | Thermodynamics of binding | Mutant NGF binding analysis |
| Western blot | TRKA phosphorylation and downstream signaling | NGF stimulation assays |
| CRISPR knockout screen | Genes required for NGF-dependent phenotypes | Functional genomics of NGF signaling |
| Immunofluorescence | Subcellular localization of NGF and receptors | Neuronal trafficking studies |
| ELISA | NGF or antibody binding levels | Anti-NGF biologic characterization |
| Behavioral pain assays | Nociceptive responses in vivo | NGF mutation phenotyping |
Binding assays for NGF-receptor interaction
Surface plasmon resonance, isothermal titration calorimetry and enzyme-linked binding assays can measure the affinity and kinetics of NGF binding to TRKA, p75NTR or engineered binders. These methods directly assess GO:0048406 activity and can be used to compare wild-type and mutant proteins.
Cell-based signaling readouts
NGF-induced TRKA autophosphorylation and downstream MAPK or AKT phosphorylation can be measured by Western blot or phospho-specific immunoassays. These readouts connect the binding event to functional outcomes and are standard in neurotrophin research.
Genetic screens and CRISPR perturbation
CRISPR knockout screens can identify genes required for NGF-dependent survival or signaling, while focused libraries can test NGF binding partners. Such screens help prioritize GO:0048406-annotated candidates for follow-up.
In vivo pain and inflammation models
Mouse models of inflammatory pain and joint inflammation can be used to test how NGF binding mutations affect behavior and tissue pathology. The NGF R100E model demonstrates that a single residue change in the binding interface can produce sex-dependent phenotypes.
How CRISPR Can Be Used to Study GO:0048406 nerve growth factor binding
Knockout
CRISPR knockout of NTRK1 or NGFR can eliminate NGF binding and reveal which downstream responses depend on each receptor. Knockout of NGF itself can be used to study autocrine or paracrine loops in cancer and neuronal models.
Point Mutation
Point mutations such as NGF R100E can be introduced to alter the binding interface and test how specific residues contribute to pain behavior, inflammation and bone erosion. This approach is powerful for dissecting structure-function relationships within GO:0048406.
Knock-in
Tagged knock-in of NTRK1 or NGFR allows endogenous labeling of the receptors for imaging, proteomics or proximity labeling without overexpression artifacts. Knock-in of reporter alleles can also provide real-time readouts of NGF binding and signaling.
Overexpression
Overexpression of NGF or its receptors can amplify signaling and is useful for studying metastasis, inflammation and neurotrophin-dependent proliferation. Overexpression models should be interpreted with care because they may not reflect physiological binding stoichiometry.
How EDITGENE Supports nerve growth factor binding Research
Researchers studying nerve growth factor binding-related genes often need to determine whether a candidate gene is causally involved in NGF-dependent phenotypes. EDITGENE provides the CRISPR tools and cell models required to move from correlation to causation, from knockout validation to precise point mutations and tagged knock-ins.
Contact EDITGENE today to design your custom CRISPR model for nerve growth factor binding research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NGFR Knockout HEK293 Cell Line | EDJ-KQ210 | Human | 4804 | Details Get a Quote |
| NTRK1 Knockout HEK293 Cell Line | EDJ-KQ719 | Human | 4914 | Details Get a Quote |
| SORT1 Knockout HEK293 Cell Line | EDJ-KQ2463 | Human | 6272 | Details Get a Quote |
| PCSK6 Knockout HEK293 Cell Line | EDJ-KQ5395 | Human | 5046 | Details Get a Quote |
| FURIN Knockout HEK293 Cell Line | EDJ-KQ12771 | Human | 5045 | Details Get a Quote |
| FURIN Knockout HeLa Cell Line | EDJ-KQ17986 | Human | 5045 | Details Get a Quote |
| SORT1 Knockout A-549 Cell Line | EDJ-KQ23014 | Human | 6272 | Details Get a Quote |
| SORT1 Knockout HCT 116 Cell Line | EDJ-KQ23015 | Human | 6272 | Details Get a Quote |
| SORT1 Knockout HeLa Cell Line | EDJ-KQ23016 | Human | 6272 | Details Get a Quote |
| FURIN Knockout A-549 Cell Line | EDJ-KQ43147 | Human | 5045 | Details Get a Quote |
| FURIN Knockout HCT 116 Cell Line | EDJ-KQ43148 | Human | 5045 | Details Get a Quote |
| NGFR Knockout HCT 116 Cell Line | EDJ-KQ19331 | Human | 4804 | Details Get a Quote |
| PCSK6 Knockout A-549 Cell Line | EDJ-KQ28539 | Human | 5046 | Details Get a Quote |
| PCSK6 Knockout HCT 116 Cell Line | EDJ-KQ28540 | Human | 5046 | Details Get a Quote |
| PCSK6 Knockout HeLa Cell Line | EDJ-KQ28541 | Human | 5046 | Details Get a Quote |
Frequently Asked Questions About nerve growth factor binding
What is GO:0048406?
GO:0048406 is the Gene Ontology molecular function term for nerve growth factor binding, defined as binding to nerve growth factor (NGF).
What genes are involved in nerve growth factor binding?
Key genes include NGF, NTRK1 (TRKA), NGFR (p75NTR), SORT1 and downstream effectors such as SHC1, PLCG1, MAPK1 and AKT1.
What is the difference between TRKA and p75NTR in NGF binding?
TRKA is a high-affinity receptor that mediates survival and differentiation signals, while p75NTR is a low-affinity receptor that modulates signaling and can influence cell fate.
How is nerve growth factor binding studied?
Common methods include surface plasmon resonance, isothermal titration calorimetry, Western blot for receptor phosphorylation, CRISPR screens and in vivo pain models.
Is nerve growth factor binding involved in disease?
Yes, it is implicated in diabetic neuropathy, alcohol use disorders, ocular allergy, inflammatory pain and colorectal cancer metastasis.
Can ATP regulate NGF binding?
Yes, ATP binding to NGF and proNGF acts as an endogenous molecular switch that can modulate neurotrophin activity.
What is the NGF R100E mutation?
It is a targeted mutation in the NGF binding interface that produces sex-dependent effects on pain behavior, joint inflammation and bone erosion in mice.
Are there therapeutic antibodies that bind NGF?
Yes, bedinvetmab is a canine anti-NGF monoclonal antibody used in veterinary medicine, demonstrating therapeutic targeting of NGF binding.
How does NGF binding promote cancer metastasis?
NGF signaling can orchestrate NGAL and matrix metalloproteinase activity, which promotes colorectal cancer metastasis.
What CRISPR models are available for NGF binding research?
Knockout, point-mutation, knock-in, tagged knock-in and overexpression models can be generated for NGF, NTRK1, NGFR and related genes.
Conclusion
GO:0048406 nerve growth factor binding is a compact but powerful molecular function term that anchors NGF biology to receptor activation, neuronal survival, pain, inflammation and cancer. Its canonical players, TRKA and p75NTR, define the signaling logic, while emerging regulators such as ATP and disease-associated mutations like NGF R100E show that the binding interface is dynamic and tunable. For researchers, the term provides a ready-made annotation framework for interpreting screens, designing CRISPR models and connecting basic neurotrophin mechanisms to human disease. EDITGENE supports this work with knockout, point-mutation, knock-in, overexpression and library screening services tailored to NGF binding-related genes.
References
- 1. Krautmann M et al.. 2021. Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs.. Vet J 276:105733 PMID: 34391918
- 2. Paoletti F. 2024. ATP binding to Nerve Growth Factor (NGF) and pro-Nerve Growth Factor (proNGF): an endogenous molecular switch modulating neurotrophins activity.. Biochem Soc Trans 52(3):1293-1304 PMID: 38716884
- 3. Ceci FM et al.. 2021. Nerve Growth Factor in Alcohol Use Disorders.. Curr Neuropharmacol 19(1):45-60 PMID: 32348226
- 4. Sacchetti M et al.. 2019. Neurotrophic factors and nerve growth factor in ocular allergy.. Curr Opin Allergy Clin Immunol 19(5):510-516 PMID: 31145195
- 5. Pittenger G et al.. 2003. Nerve growth factor and diabetic neuropathy.. Exp Diabesity Res 4(4):271-85 PMID: 14668049
- 6. Morado-Urbina CE et al.. 2024. Sex-dependent effects of the targeted nerve growth factor mutation (R100E) on pain behavior, joint inflammation, and bone erosion in mice.. Pain 165(12):2814-2828 PMID: 39324959
- 7. Wiesmann C et al.. 2001. Nerve growth factor: structure and function.. Cell Mol Life Sci 58(5-6):748-59 PMID: 11437236
- 8. Lei Y et al.. 2022. Nerve growth factor orchestrates NGAL and matrix metalloproteinases activity to promote colorectal cancer metastasis.. Clin Transl Oncol 24(1):34-47 PMID: 34255268
